IOL Chemicals and Pharmaceuticals Ltd
Chemicals are 40 percent of its portfolio. It hopes to launch more products in the segment.
It reported subdued earnings for the March-ended quarter. Its margins have fallen led by a weak performance by the pharma segment while the chemical segment drove the overall growth.
It is in a transition phase where both the chemicals and pharma product portfolio is growing but pharma will grow faster than the chemicals and that will drive a higher percentage of our sales going forward.
It delivered 30 percent margins in FY21 and will be close to that number in CFY as well.